» Articles » PMID: 37287056

Significant Improvement of Bone Marrow-derived MSC Expansion from MDS Patients by Defined Xeno-free Medium

Abstract

Background: Robust and reliable in vitro and in vivo models of primary cells are necessary to study the pathomechanisms of Myelodysplastic Neoplasms (MDS) and identify novel therapeutic strategies. MDS-derived hematopoietic stem and progenitor cells (HSPCs) are reliant on the support of bone marrow (BM) derived mesenchymal stroma cells (MSCs). Therefore, isolation and expansion of MCSs are essential for successfully modeling this disease. For the clinical use of healthy MSCs isolated from human BM, umbilical cord blood or adipose tissue, several studies showed that xeno-free (XF) culture conditions resulted in superior growth kinetics compared to MSCs cultured in the presence of fetal bovine serum (FBS). In this present study, we investigate, whether the replacement of a commercially available MSC expansion medium containing FBS with a XF medium is beneficial for the expansion of MSCs derived from BM of MDS patients which are often difficult to cultivate.

Methods: MSCs isolated from BM of MDS patients were cultured and expanded in MSC expansion medium with FBS or XF supplement. Subsequently, the impact of culture media on growth kinetics, morphology, immunophenotype, clonogenic potential, differentiation capacity, gene expression profiles and ability to engraft in immunodeficient mouse models was evaluated.

Results: Significant higher cell numbers with an increase in clonogenic potential were observed during culture of MDS MSCs with XF medium compared to medium containing FBS. Differential gene expression showed an increase in transcripts associated with MSC stemness after expansion with XF. Furthermore, immunophenotypes of the MSCs and their ability to differentiate into osteoblasts, adipocytes or chondroblasts remained stable. MSCs expanded with XF media were similarly supportive for creating MDS xenografts in vivo as MSCs expanded with FBS.

Conclusion: Our data indicate that with XF media, higher cell numbers of MDS MSCs can be obtained with overall improved characteristics in in vitro and in vivo experimental models.

Citing Articles

Extracellular Vesicles from Mesenchymal Stem Cells: Potential as Therapeutics in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Zou X, Brigstock D Biomedicines. 2025; 12(12.

PMID: 39767754 PMC: 11673942. DOI: 10.3390/biomedicines12122848.


Genes Selectively Expressed in Rat Organs.

Li D, Wan X, Yun Y, Li Y, Duan W Curr Genomics. 2024; 25(4):261-297.

PMID: 39156728 PMC: 11327808. DOI: 10.2174/0113892029273121240401060228.


The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review.

cesnik A, Svajger U Front Cell Dev Biol. 2024; 12:1400347.

PMID: 39129786 PMC: 11310176. DOI: 10.3389/fcell.2024.1400347.

References
1.
Mian S, Abarrategi A, Kong K, Rouault-Pierre K, Wood H, Oedekoven C . Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells. Blood Cancer Discov. 2021; 2(2):135-145. PMC: 7610449. DOI: 10.1158/2643-3230.BCD-20-0161. View

2.
Jann J, Mossner M, Riabov V, Altrock E, Schmitt N, Flach J . Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo. Nat Commun. 2021; 12(1):6170. PMC: 8546146. DOI: 10.1038/s41467-021-26424-3. View

3.
Cazzola M . Myelodysplastic Syndromes. N Engl J Med. 2020; 383(14):1358-1374. DOI: 10.1056/NEJMra1904794. View

4.
Lindroos B, Boucher S, Chase L, Kuokkanen H, Huhtala H, Haataja R . Serum-free, xeno-free culture media maintain the proliferation rate and multipotentiality of adipose stem cells in vitro. Cytotherapy. 2009; 11(7):958-72. DOI: 10.3109/14653240903233081. View

5.
Shultz L, Lyons B, Burzenski L, Gott B, Chen X, Chaleff S . Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174(10):6477-89. DOI: 10.4049/jimmunol.174.10.6477. View